Flashy moves aren't always the best moves in med-tech. Medtronic (NYSE: MDT )
shelled out big bucks for Aterial Vascular Engineering, CoreValve, and
Ardian, and the first two led to significant patent infringement issues
and the third may never lead to a marketable product (renal
denervation). I don't want to pick on Medtronic alone, as Hologic, Johnson & Johnson, and Boston Scientific (NYSE: BSX ) have all made some big deals that went south and squandered shareholder capital.
With that in mind, I like the recent updates from Boston
Scientific. Between two clinical trial updates and a small acquisition,
Boston Scientific is laying the groundwork for what should be some good
incremental revenue and profit growth in the coming years. I don't
believe these items are enough to vault the company's stock to the level
of great buy, but they are positive developments nevertheless.
Continue here:
Good News at Boston Scientific: What's Next
No comments:
Post a Comment